<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="market [ 3], including 30 mAbs for the treatment of" exact="cancer" post="(Table 1). Table 1 US FDA-approved monoclonal antibody on"/>
 <result pre="F. Hoffmann-La Roche Ltd./Genentech Inc. CD20 Chimeric IgG1 Hybridoma Non-Hodgkin" exact="lymphoma" post="1997 Palivizumab Synagis MedImmune/AbbVie Inc. RSV Humanized IgG1 Hybridoma"/>
 <result pre="F. Hoffmann-La Roche, Ltd./Genentech Inc. HER2 Humanized IgG1 Hybridoma Breast" exact="cancer" post="1998 Alemtuzumab Campath, Lemtrada Berlex Inc./Genzyme Corp./Millennium Pharmaceuticals Inc."/>
 <result pre="Berlex Inc./Genzyme Corp./Millennium Pharmaceuticals Inc. CD52 Humanized IgG1 Hybridoma Chronic" exact="myeloid leukemia" post="2001 Adalimumab Humira AbbVie Inc. TNFα Human IgG1 Phage"/>
 <result pre="Inc./Genzyme Corp./Millennium Pharmaceuticals Inc. CD52 Humanized IgG1 Hybridoma Chronic myeloid" exact="leukemia" post="2001 Adalimumab Humira AbbVie Inc. TNFα Human IgG1 Phage"/>
 <result pre="Adalimumab Humira AbbVie Inc. TNFα Human IgG1 Phage display Rheumatoid" exact="arthritis" post="2002 Ibritumomab tiuxetan Zevalin Biogen Inc./Schering AG/Spectrum Pharmaceuticals Inc."/>
 <result pre="Biogen Inc./Schering AG/Spectrum Pharmaceuticals Inc. CD20 Murine IgG1 Hybridoma Non-Hodgkin" exact="lymphoma" post="2002 Omalizumab Xolair Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc./Novartis"/>
 <result pre="Co. Inc./Eli Lilly/ImClone Systems Inc. EGFR Chimeric IgG1 Hybridoma Colorectal" exact="cancer" post="2004 Bevacizumab Avastin Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc."/>
 <result pre="F. Hoffmann-La Roche, Ltd./Genentech Inc. VEGF-A Humanized IgG1 Hybridoma Colorectal" exact="cancer" post="2004 Natalizumab Tysabri Biogen Inc./Elan Pharmaceuticals International, Ltd. ITGA4"/>
 <result pre="2004 Panitumumab Vectibix Amgen EGFR Human IgG2 Transgenic mice Colorectal" exact="cancer" post="2006 Ranibizumab Lucentis Roche, F. Hoffmann-La Roche Ltd./Genentech Inc./Novartis"/>
 <result pre="Soliris Alexion Pharmaceuticals Inc. C5 Humanized IgG2/4 Hybridoma Paroxysmal nocturnal" exact="hemoglobinuria" post="2007 Certolizumab pegol Cimzia Celltech, UCB. TNFα Humanized Fab,"/>
 <result pre="Inc./Janssen Biotech Inc. TNFα Human IgG1 Transgenic mice Rheumatoid and" exact="psoriatic arthritis," post="ankylosing spondylitis 2009 Ofatumumab Arzerra Genmab A/S /GlaxoSmithKline /Novartis."/>
 <result pre="Inc. TNFα Human IgG1 Transgenic mice Rheumatoid and psoriatic arthritis," exact="ankylosing spondylitis" post="2009 Ofatumumab Arzerra Genmab A/S /GlaxoSmithKline /Novartis. CD20 Human"/>
 <result pre="TNFα Human IgG1 Transgenic mice Rheumatoid and psoriatic arthritis, ankylosing" exact="spondylitis" post="2009 Ofatumumab Arzerra Genmab A/S /GlaxoSmithKline /Novartis. CD20 Human"/>
 <result pre="A/S /GlaxoSmithKline /Novartis. CD20 Human IgG1 Transgenic mice Chronic lymphocytic" exact="leukemia" post="2009 Tocilizumab RoActemra, Actemra Chugai Pharmaceutical Co., Ltd./Roche, F."/>
 <result pre="F. Hoffmann-La Roche. Ltd./Genentech Inc. IL-6R Humanized IgG1 Hybridoma Rheumatoid" exact="arthritis" post="2010 Denosumab Xgeva, Prolia Amgen RANKL Human IgG2 Transgenic"/>
 <result pre="/Human Genome Sciences Inc. BLyS Human IgG1 Phage display Systemic" exact="lupus erythematosus" post="2011 Ipilimumab Yervoy Bristol-Myers Squibb/Medarex CTLA-4 Human IgG1 Transgenic"/>
 <result pre="Chimeric IgG1; ADC Hybridoma Hodgkin lymphoma, systemic anaplastic large cell" exact="lymphoma" post="2011 Pertuzumab Perjeta Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc."/>
 <result pre="Roche Ltd./Genentech Inc./ImmunoGen Inc. HER2 Humanized IgG1; ADC Hybridoma Breast" exact="cancer" post="2012 Raxibacumab Abthrax GlaxoSmithKline /Human Genome Sciences Inc. (HGSI)"/>
 <result pre="Roche, Ltd./Genentech Inc. CD20 Humanized IgG1 Glycoengineered Hybridoma Chronic lymphocytic" exact="leukemia" post="2013 Siltuximab Sylvant Centocor Inc./Janssen Biotech Inc./Janssen-Cilag International NV"/>
 <result pre="Eli Lilly/ImClone Systems Inc. VEGFR2 Human IgG1 Phage display Gastric" exact="cancer" post="2014 Vedolizumab Entyvio Genentech Inc./Millennium Pharmaceuticals Inc./Takeda Pharmaceuticals U.S.A."/>
 <result pre="Blincyto Amgen CD19, CD3 Murine bispecific tandem scFv Hybridoma Acute" exact="lymphoblastic leukemia" post="2014 Nivolumab Opdivo Bristol-Myers Squibb/Ono Pharmaceutical Co., Ltd. PD-1"/>
 <result pre="Amgen CD19, CD3 Murine bispecific tandem scFv Hybridoma Acute lymphoblastic" exact="leukemia" post="2014 Nivolumab Opdivo Bristol-Myers Squibb/Ono Pharmaceutical Co., Ltd. PD-1"/>
 <result pre="Co., Ltd. PD-1 Human IgG4 Transgenic mice Melanoma, non-small cell" exact="lung cancer" post="2014 Pembrolizumab Keytruda Merck &amp;amp; Co. Inc. PD-1 Humanized"/>
 <result pre="Ltd. PD-1 Human IgG4 Transgenic mice Melanoma, non-small cell lung" exact="cancer" post="2014 Pembrolizumab Keytruda Merck &amp;amp; Co. Inc. PD-1 Humanized"/>
 <result pre="Lilly/ImClone Systems Inc. EGFR Human IgG1 Phage display Non-small cell" exact="lung cancer" post="2015 Dinutuximab Unituxin United Therapeutics Corporation GD2 Chimeric IgG1"/>
 <result pre="Systems Inc. EGFR Human IgG1 Phage display Non-small cell lung" exact="cancer" post="2015 Dinutuximab Unituxin United Therapeutics Corporation GD2 Chimeric IgG1"/>
 <result pre="Mepolizumab Nucala Centocor Inc./GlaxoSmithKline IL-5 Humanized IgG1 Hybridoma Severe eosinophilic" exact="asthma" post="2015 Alirocumab Praluent Regeneron Pharmaceuticals Inc./Sanofi. PCSK9 Human IgG1"/>
 <result pre="Lilly/ImClone Systems Inc. PDGFRα Human IgG1 Transgenic mice Soft tissue" exact="sarcoma" post="2016 Bezlotoxumab Zinplava Merck &amp;amp; Co. Inc. Clostridium difficile"/>
 <result pre="F. Hoffmann-La Roche, Ltd./Genentech Inc. PD-L1 Humanized IgG1 Hybridoma Bladder" exact="cancer" post="2016 Obiltoxaximab Anthim Elusys Therapeutics Inc. B. anthrasis PA"/>
 <result pre="Inc. B. anthrasis PA Chimeric IgG1 Hybridoma Prevention of inhalational" exact="anthrax" post="2016 Inotuzumab ozogamicin Besponsa Wyeth Pharmaceuticals/Pfizer. CD22 Humanized IgG4"/>
 <result pre="Inotuzumab ozogamicin Besponsa Wyeth Pharmaceuticals/Pfizer. CD22 Humanized IgG4 Hybridoma Acute" exact="lymphoblastic leukemia" post="2017 Brodalumab Siliq, Lumicef MedImmune/Amgen/Kyowa Hakko Kirin /AstraZeneca/Valeant Pharmaceuticals"/>
 <result pre="ozogamicin Besponsa Wyeth Pharmaceuticals/Pfizer. CD22 Humanized IgG4 Hybridoma Acute lymphoblastic" exact="leukemia" post="2017 Brodalumab Siliq, Lumicef MedImmune/Amgen/Kyowa Hakko Kirin /AstraZeneca/Valeant Pharmaceuticals"/>
 <result pre="/AstraZeneca/Valeant Pharmaceuticals International Inc. IL-17R Human IgG2 Transgenic mice Plaque" exact="psoriasis" post="2017 Guselkumab Tremfya MorphoSys/Janssen Biotech Inc. IL-23 p19 Human"/>
 <result pre="MorphoSys/Janssen Biotech Inc. IL-23 p19 Human IgG1 Phage display Plaque" exact="psoriasis" post="2017 Dupilumab Dupixent Regeneron Pharmaceuticals Inc./Sanofi IL-4Rα Human IgG4"/>
 <result pre="Dupixent Regeneron Pharmaceuticals Inc./Sanofi IL-4Rα Human IgG4 Transgenic mice Atopic" exact="dermatitis" post="2017 Sarilumab Kevzara Regeneron Pharmaceuticals Inc./Sanofi IL-6R Human IgG1"/>
 <result pre="Kevzara Regeneron Pharmaceuticals Inc./Sanofi IL-6R Human IgG1 Transgenic mice Rheumatoid" exact="arthritis" post="2017 Avelumab Bavencio Merck Serono International S.A./Pfizer PD-L1 Human"/>
 <result pre="Gemtuzumab ozogamicin Mylotarg Pfizer CD33 Humanized IgG4; ADC Hybridoma Acute" exact="myeloid leukemia" post="2017 Durvalumab Imfinzi MedImmune/AstraZeneca PD-L1 Human IgG1 Transgenic mice"/>
 <result pre="ozogamicin Mylotarg Pfizer CD33 Humanized IgG4; ADC Hybridoma Acute myeloid" exact="leukemia" post="2017 Durvalumab Imfinzi MedImmune/AstraZeneca PD-L1 Human IgG1 Transgenic mice"/>
 <result pre="2017 Durvalumab Imfinzi MedImmune/AstraZeneca PD-L1 Human IgG1 Transgenic mice Bladder" exact="cancer" post="2017 Burosumab Crysvita Kyowa Hakko Kirin/Ultragenyx Pharmaceutical Inc. FGF23"/>
 <result pre="Hakko Kirin/Ultragenyx Pharmaceutical Inc. FGF23 Human IgG1 Transgenic mice X-linked" exact="hypophosphatemia" post="2018 Lanadelumab Takhzyro Dyax Corp. Plasma kallikrein Human IgG1"/>
 <result pre="Takhzyro Dyax Corp. Plasma kallikrein Human IgG1 Phage display Hereditary" exact="angioedema" post="attacks 2018 Mogamulizumab Poteligeo Kyowa Hakko Kirin CCR4 Humanized"/>
 <result pre="Inc./Sun Pharmaceutical Industries, Ltd. IL-23 p19 Humanized IgG1 Hybridoma Plaque" exact="psoriasis" post="2018 Cemiplimab Libtayo Regeneron Pharmaceuticals Inc. PD-1 Human mAb"/>
 <result pre="2018 Emapalumab Gamifant NovImmmune IFNγ Human IgG1 Phage display Primary" exact="hemophagocytic lymphohistiocytosis" post="2018 Fremanezumab Ajovy Teva Pharmaceutical Industries, Ltd. CGRP Humanized"/>
 <result pre="Lumoxiti MedImmune/AstraZeneca CD22 Murine IgG1 dsFv Phage display Hairy cell" exact="leukemia" post="2018 Ravulizumab Ultomiris Alexion Pharmaceuticals Inc. C5 humanized IgG2/4"/>
 <result pre="Ultomiris Alexion Pharmaceuticals Inc. C5 humanized IgG2/4 Hybridoma Paroxysmal nocturnal" exact="hemoglobinuria" post="2018 Caplacizumab Cablivi Ablynx von Willebrand factor Humanized Nanobody"/>
 <result pre="Caplacizumab Cablivi Ablynx von Willebrand factor Humanized Nanobody Hybridoma Acquired" exact="thrombotic thrombocytopenic purpura" post="2019 Romosozumab Evenity Amgen/UCB Sclerostin Humanized IgG2 Hybridoma Osteoporosis"/>
 <result pre="Ablynx von Willebrand factor Humanized Nanobody Hybridoma Acquired thrombotic thrombocytopenic" exact="purpura" post="2019 Romosozumab Evenity Amgen/UCB Sclerostin Humanized IgG2 Hybridoma Osteoporosis"/>
 <result pre="Ingelheim Pharmaceuticals/ AbbVie Inc. IL-23 p19 Humanized IgG1 Hybridoma Plaque" exact="psoriasis" post="2019 Polatuzumab vedotin Polivy Roche, F. Hoffmann-La Roche, Ltd."/>
 <result pre="Roche, Ltd. CD79β Humanized IgG1 ADC Hybridoma Diffuse large B-cell" exact="lymphoma" post="2019 Brolucizumab Beovu Novartis Pharmaceuticals Corp. VEGF-A Humanized scFv"/>
 <result pre="2018. Ab, antibody; ALCL, systematic anaplastic large-cell lymphoma; aTTP, acquired" exact="thrombotic thrombocytopenic purpura;" post="BC, breast cancer; CD, cluster of differentiation; CGRP, calcitonin"/>
 <result pre="systematic anaplastic large-cell lymphoma; aTTP, acquired thrombotic thrombocytopenic purpura; BC," exact="breast cancer;" post="CD, cluster of differentiation; CGRP, calcitonin gene-related peptide; CGRPR,"/>
 <result pre="CGRP, calcitonin gene-related peptide; CGRPR, calcitonin gene-related peptide receptor; CRC," exact="colorectal cancer;" post="CTLA-4, cytotoxic T-lymphocyte-associated protein 4; EGFR, epidermal growth factor"/>
 <result pre="receptor; mAb, monoclonal antibody; MCC, merkel-cell carcinoma; NSCLC, non-small cell" exact="lung cancer;" post="PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand"/>
 <result pre="PD-L1, programmed death-ligand 1; TNFα, tumor necrosis factor α; RA," exact="rheumatoid arthritis;" post="RANKL, receptor activator of nuclear factor kappa-B ligand; VEGF-A,"/>
 <result pre="growth factor receptor 2; vWF, von Willebrand factor; XLH, X-linked" exact="hypophosphatemia" post="The first therapeutic mAb, muromonab-CD3 (Orthoclone OKT3), was approved"/>
 <result pre="oncologic indication, rituximab, a chimeric anti-CD20 IgG1 approved for non-Hodgkin’s" exact="lymphoma" post="in 1997 by US FDA (Fig. 1) [ 8,"/>
 <result pre="biologics directed against diseases that require long-term treatment, such as" exact="cancer" post="and autoimmune diseases [ 12]. Based on the success"/>
 <result pre="16], was approved in 2002 by the US FDA for" exact="rheumatoid arthritis" post="(Fig. 1). Until now, nine human antibody drugs generated"/>
 <result pre="was approved in 2002 by the US FDA for rheumatoid" exact="arthritis" post="(Fig. 1). Until now, nine human antibody drugs generated"/>
 <result pre="from human B cells has also yielded promising results for" exact="infectious disease" post="therapeutics. The recent development of bispecific antibodies offers attractive"/>
 <result pre="that targets CD3 and CD19 for treatment of B-cell precursor" exact="acute lymphoblastic leukemia" post="(ALL) [ 42]. Second, emicizumab is a full-size bispecific"/>
 <result pre="targets CD3 and CD19 for treatment of B-cell precursor acute" exact="lymphoblastic leukemia" post="(ALL) [ 42]. Second, emicizumab is a full-size bispecific"/>
 <result pre="CD3 and CD19 for treatment of B-cell precursor acute lymphoblastic" exact="leukemia" post="(ALL) [ 42]. Second, emicizumab is a full-size bispecific"/>
 <result pre="clinical trials, about 86% of which are under evaluation as" exact="cancer" post="therapies [ 40]. The concepts and platforms driving the"/>
 <result pre="such as cancer, asthma, arthritis, psoriasis, Crohn’s disease, transplant rejection," exact="migraine" post="headaches and infectious diseases (Table 1). Important advances in"/>
 <result pre="Approval Year) Company 2018 Revenue (USD) 1 Adalimumab (Humira) Rheumatoid" exact="arthritis" post="(2002) Psoriatic arthritis (2005) Ankylosing spondylitis (2006) Juvenile Idiopathic"/>
 <result pre="2018 Revenue (USD) 1 Adalimumab (Humira) Rheumatoid arthritis (2002) Psoriatic" exact="arthritis" post="(2005) Ankylosing spondylitis (2006) Juvenile Idiopathic Arthitis (2008) Psoriasis"/>
 <result pre="1 Adalimumab (Humira) Rheumatoid arthritis (2002) Psoriatic arthritis (2005) Ankylosing" exact="spondylitis" post="(2006) Juvenile Idiopathic Arthitis (2008) Psoriasis (2008) Crohn’s disease"/>
 <result pre="Juvenile Idiopathic Arthitis (2008) Psoriasis (2008) Crohn’s disease (2010) Ulcerative" exact="colitis" post="(2012) Hidradenitis suppurativa (2015) Uveitis (2018) AbbVie $19.9 bn"/>
 <result pre="AbbVie $19.9 bn 2 Nivolumab (Opdivo) Melanoma (2015) Non-small cell" exact="lung cancer" post="(2015) Renal cell carcinoma (2015) Head and neck squamous"/>
 <result pre="$19.9 bn 2 Nivolumab (Opdivo) Melanoma (2015) Non-small cell lung" exact="cancer" post="(2015) Renal cell carcinoma (2015) Head and neck squamous"/>
 <result pre="$7.6 bn 3 Pembrolizumab (Keytruda) Melanoma (2014) Head and neck" exact="cancer" post="(2016) Non-small cell lung caccer (2015) Lymphoma (2018) Cervical"/>
 <result pre="cancer (2016) Non-small cell lung caccer (2015) Lymphoma (2018) Cervical" exact="cancer" post="(2018) Microsatellite instability-high cancer (2018) Merck &amp;amp; Co $7.2"/>
 <result pre="lung caccer (2015) Lymphoma (2018) Cervical cancer (2018) Microsatellite instability-high" exact="cancer" post="(2018) Merck &amp;amp; Co $7.2 bn 4 Trastuzumab (Herceptin)"/>
 <result pre="(2018) Merck &amp;amp; Co $7.2 bn 4 Trastuzumab (Herceptin) Breast" exact="cancer" post="(1998) Gastric cancer (2010) Roche $7.0 bn 5 Bevacizumab"/>
 <result pre="Co $7.2 bn 4 Trastuzumab (Herceptin) Breast cancer (1998) Gastric" exact="cancer" post="(2010) Roche $7.0 bn 5 Bevacizumab (Avastin) Colorectal cancer"/>
 <result pre="Gastric cancer (2010) Roche $7.0 bn 5 Bevacizumab (Avastin) Colorectal" exact="cancer" post="(2004) Non-small cell lung caccer (2006) Breast ERB2 negative"/>
 <result pre="cancer (2004) Non-small cell lung caccer (2006) Breast ERB2 negative" exact="cancer" post="(2008) Renal cell carcinoma (2009) Glioblastoma (2011) Roche $6.8"/>
 <result pre="(2009) Glioblastoma (2011) Roche $6.8 bn 6 Rituximab, (Rituxan) Non-Hodgkin’s" exact="lymphoma" post="(1997) Chronic lymphocytic leukemia (2010) Rheumatoid arthritis (2006) Pemphigus"/>
 <result pre="$6.8 bn 6 Rituximab, (Rituxan) Non-Hodgkin’s lymphoma (1997) Chronic lymphocytic" exact="leukemia" post="(2010) Rheumatoid arthritis (2006) Pemphigus vulgaris (2018) Roche $6.8"/>
 <result pre="Rituximab, (Rituxan) Non-Hodgkin’s lymphoma (1997) Chronic lymphocytic leukemia (2010) Rheumatoid" exact="arthritis" post="(2006) Pemphigus vulgaris (2018) Roche $6.8 bn 7 Infliximab"/>
 <result pre="Roche $6.8 bn 7 Infliximab (Remicade) Crohn’s Disease (1998) Rheumatoid" exact="arthritis" post="(1999) Ankylosing spondylitis (2004) Ulcerative colitis (2005) Psoriatic arthritis"/>
 <result pre="7 Infliximab (Remicade) Crohn’s Disease (1998) Rheumatoid arthritis (1999) Ankylosing" exact="spondylitis" post="(2004) Ulcerative colitis (2005) Psoriatic arthritis (2005) Psoriasis (2006)"/>
 <result pre="Crohn’s Disease (1998) Rheumatoid arthritis (1999) Ankylosing spondylitis (2004) Ulcerative" exact="colitis" post="(2005) Psoriatic arthritis (2005) Psoriasis (2006) Johnson &amp;amp; Johnson"/>
 <result pre="Rheumatoid arthritis (1999) Ankylosing spondylitis (2004) Ulcerative colitis (2005) Psoriatic" exact="arthritis" post="(2005) Psoriasis (2006) Johnson &amp;amp; Johnson $5.9 bn 8"/>
 <result pre="&amp;amp; Johnson $5.9 bn 8 Ustekinumab (Stelara) Psoriasis (2009) Psoriatic" exact="arthritis" post="(2013) Crohn’s Disease (2016) Johnson &amp;amp; Johnson $5.2 bn"/>
 <result pre="Johnson &amp;amp; Johnson $5.2 bn 9 Eculizumab (Soliris) Paroxysmal nocturnal" exact="hemoglobinuria" post="(2007) Atypical hemolytic uremic syndrome (2011) Generalized myasthenia gravis"/>
 <result pre="Paroxysmal nocturnal hemoglobinuria (2007) Atypical hemolytic uremic syndrome (2011) Generalized" exact="myasthenia gravis" post="(2017) Neuromyelitis optica spectrum disorder (2019) Alexion $3.6 bn"/>
 <result pre="Alexion $3.6 bn 10 Omalizumab (Xolair) Asthma (2003) Chronic idiopathic" exact="urticaria" post="(2014) Roche $3.0 bn bn, billion mAbs are increasingly"/>
 <result pre="subcutaneously administered biological disease modifier used for the treatment of" exact="rheumatoid arthritis" post="and other TNFα-mediated chronic debilitating diseases. It was originally"/>
 <result pre="administered biological disease modifier used for the treatment of rheumatoid" exact="arthritis" post="and other TNFα-mediated chronic debilitating diseases. It was originally"/>
 <result pre="Adalimumab reduces the signs and symptoms of moderate to severe" exact="rheumatoid arthritis" post="in adults, and it is also used to treat"/>
 <result pre="reduces the signs and symptoms of moderate to severe rheumatoid" exact="arthritis" post="in adults, and it is also used to treat"/>
 <result pre="arthritis in adults, and it is also used to treat" exact="psoriatic arthritis," post="ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa,"/>
 <result pre="adults, and it is also used to treat psoriatic arthritis," exact="ankylosing spondylitis," post="Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and"/>
 <result pre="also used to treat psoriatic arthritis, ankylosing spondylitis, Crohn's disease," exact="ulcerative colitis," post="psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis ["/>
 <result pre="treat psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis," exact="hidradenitis suppurativa," post="uveitis, and juvenile idiopathic arthritis [ 47, 48]. It"/>
 <result pre="spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and" exact="juvenile idiopathic arthritis" post="[ 47, 48]. It may be used alone or"/>
 <result pre="disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic" exact="arthritis" post="[ 47, 48]. It may be used alone or"/>
 <result pre="the molecules underlying checkpoints have recently drawn considerable interest in" exact="cancer" post="immunotherapy [ 50]. Both nivolumab (Opdivo) and pembrolizumab (Keytruda)"/>
 <result pre="a signal that normally prevents activated T cells from attacking" exact="cancer" post="cells. The target for nivolumab is the PD-1 receptor,"/>
 <result pre="[ 51, 52]. Pembrolizumab is a humanized antibody used in" exact="cancer" post="immunotherapy to treat melanoma, lung cancer, head and neck"/>
 <result pre="a humanized antibody used in cancer immunotherapy to treat melanoma," exact="lung cancer," post="head and neck cancer, Hodgkin’s lymphoma, and stomach cancer"/>
 <result pre="antibody used in cancer immunotherapy to treat melanoma, lung cancer," exact="head and neck cancer," post="Hodgkin’s lymphoma, and stomach cancer [ 53– 55]. Pembrolizumab"/>
 <result pre="melanoma, lung cancer, head and neck cancer, Hodgkin’s lymphoma, and" exact="stomach cancer" post="[ 53– 55]. Pembrolizumab is a first-line treatment for"/>
 <result pre="lung cancer, head and neck cancer, Hodgkin’s lymphoma, and stomach" exact="cancer" post="[ 53– 55]. Pembrolizumab is a first-line treatment for"/>
 <result pre="53– 55]. Pembrolizumab is a first-line treatment for NSCLC if" exact="cancer" post="cells overexpresse PD-L1 and have no mutations in EGFR"/>
 <result pre="PD-L1 and have no mutations in EGFR or in anaplastic" exact="lymphoma" post="kinase [ 56, 57]. Large randomized clinical trials indicated"/>
 <result pre="diseases. Three antibodies (erenumab, galcanezumab, and fremaezumab) were approved for" exact="migraine" post="prevention, and one (Ibalizumab) is used for human immunodeficiency"/>
 <result pre="block the activity of calcitonin gene-related peptide (CGRP) receptor in" exact="migraine" post="etiology [ 59]. CGRP acts through a heteromeric receptor,"/>
 <result pre="the US FDA: raxibacumab and obiltoxaximab for treatment of inhalational" exact="anthrax" post="[ 63], palivizumab for prevention of respiratory syncytial virus"/>
 <result pre="Most of the mAbs in Phase I (~ 70%) are for" exact="cancer" post="treatment, and the proportions of mAbs intended to treat"/>
 <result pre="cancer treatment, and the proportions of mAbs intended to treat" exact="cancer" post="are similar for those currently in Phase II and"/>
 <result pre="were 33 novel antibody therapeutics in late-stage clinical studies for" exact="cancer" post="indications in 2018. Antibody therapeutics for solid tumors clearly"/>
 <result pre="chimeric mAb under evaluation as a treatment for patients with" exact="multiple myeloma" post="(MM). Combinations of isatuximab and different chemotherapies are being"/>
 <result pre="6 weeks thereafter in four patient cohorts: microsatellite instability high (MSI-H)" exact="endometrial cancer," post="MSI-H non-endometrial cancer, microsatellite-stable endometrial cancer, and non-small cell"/>
 <result pre="microsatellite instability high (MSI-H) endometrial cancer, MSI-H non-endometrial cancer, microsatellite-stable" exact="endometrial cancer," post="and non-small cell lung cancer. Dostarlimab is also being"/>
 <result pre="cancer, MSI-H non-endometrial cancer, microsatellite-stable endometrial cancer, and non-small cell" exact="lung cancer." post="Dostarlimab is also being evaluated in another Phase III"/>
 <result pre="as first-line treatment of Stage III or IV non-mucinous epithelial" exact="ovarian cancer" post="[ 69]. Ublituximab is a glyco-engineered anti-CD20 antibody currently"/>
 <result pre="first-line treatment of Stage III or IV non-mucinous epithelial ovarian" exact="cancer" post="[ 69]. Ublituximab is a glyco-engineered anti-CD20 antibody currently"/>
 <result pre="of ublituximab compared to teriflunomide in 440 patients with relapsing" exact="multiple sclerosis" post="[ 70]. Methodologies for developing therapeutic antibodies Human, humanized,"/>
 <result pre="patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic" exact="breast cancer" post="and gastroesophageal junction adenocarcinoma [ 57, 58]. Immunogenicity of"/>
 <result pre="with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast" exact="cancer" post="and gastroesophageal junction adenocarcinoma [ 57, 58]. Immunogenicity of"/>
 <result pre="example, ADA was detected in 0.5% of women with metastatic" exact="breast cancer," post="who were treated with Trastuzumab during their therapeutic courses"/>
 <result pre="the ADA rates were 7.1% (21/296) in the HER-2 positive" exact="breast cancer" post="patients with treatment of Trastuzumab [ 87]. The variation"/>
 <result pre="ADA rates were 7.1% (21/296) in the HER-2 positive breast" exact="cancer" post="patients with treatment of Trastuzumab [ 87]. The variation"/>
 <result pre="fully human anti-TNFα antibody, combining with methotrexate for treatment of" exact="rheumatoid arthritis" post="cause 16% of patients producing anti-drug antibodies [ 91]."/>
 <result pre="human anti-TNFα antibody, combining with methotrexate for treatment of rheumatoid" exact="arthritis" post="cause 16% of patients producing anti-drug antibodies [ 91]."/>
 <result pre="these cells are often referred as tumor initiating cells or" exact="cancer" post="stem cells (CSCs) [ 111]. Phage display technology is"/>
 <result pre="clinical use. Phage display technology has been used to probe" exact="cancer" post="tissue biopsies in order to generate antibody fragments that"/>
 <result pre="immunoliposomes have been demonstrated to provide conventional liposomal drugs with" exact="cancer" post="targeting ability, which can increase the therapeutic efficacy of"/>
 <result pre="internalizing epitopes, wherein a phage-displayed library was incubated with living" exact="cancer" post="cells at 37 °C [ 123]. This method was successfully"/>
 <result pre="identify a few antibodies with broad neutralizing activity against pandemic" exact="influenza" post="virus [ 130, 131]. Chen et al. reported the"/>
 <result pre="from the PBMCs of convalescent patients infected with a novel" exact="influenza" post="A virus H7N9, which broke out in 2013. Using"/>
 <result pre="is approved to treat inflammatory diseases, such as rheumatoid and" exact="psoriatic arthritis," post="Crohn’s disease, and psoriasis. Adalimumab is the world’s best-selling"/>
 <result pre="induces B cell proliferation and differentiation that positively correlate with" exact="systemic lupus erythematosus" post="(SLE). This anti-BLYS antibody was named belimumab and marketed"/>
 <result pre="B cell proliferation and differentiation that positively correlate with systemic" exact="lupus erythematosus" post="(SLE). This anti-BLYS antibody was named belimumab and marketed"/>
 <result pre="tumor angiogenesis, but it also expressed on the surface of" exact="cancer" post="cells. The anti-VEGFR2 human antibody, ramucirumab (Cyramza), was approved"/>
 <result pre="for the treatment of gastric cancer, metastatic NSCLC and metastatic" exact="colorectal cancer" post="[ 145, 146]. The development of ramucirumab was initiated"/>
 <result pre="the treatment of gastric cancer, metastatic NSCLC and metastatic colorectal" exact="cancer" post="[ 145, 146]. The development of ramucirumab was initiated"/>
 <result pre="have been found to express PD-L1 on the surface of" exact="cancer" post="cells, using the immune-suppressing action to evade immune attacks."/>
 <result pre="of urothelial carcinoma and Merkel-cell carcinoma, an aggressive type of" exact="skin cancer" post="[ 151]. Psoriasis is a chronic autoimmune inflammatory disorder"/>
 <result pre="urothelial carcinoma and Merkel-cell carcinoma, an aggressive type of skin" exact="cancer" post="[ 151]. Psoriasis is a chronic autoimmune inflammatory disorder"/>
 <result pre="approval by the US FDA for the treatment of plaque" exact="psoriasis" post="[ 154]. Hereditary angioedema is a rare disease that"/>
 <result pre="FDA for the treatment of plaque psoriasis [ 154]. Hereditary" exact="angioedema" post="is a rare disease that results in spontaneous, recurrent,"/>
 <result pre="in the USA and Canada for prophylaxis against attacks of" exact="hereditary angioedema" post="in patients aged ≥ 12 years [ 157]. The success of"/>
 <result pre="the USA and Canada for prophylaxis against attacks of hereditary" exact="angioedema" post="in patients aged ≥ 12 years [ 157]. The success of"/>
 <result pre="wide spectrum of target antigens, including pure recombinant proteins, glycans," exact="cancer" post="cells and virus particles [ 99, 103, 104]. Human"/>
 <result pre="market (Table 5). Eight of the drugs are used for" exact="cancer" post="treatment, while the others are for autoimmune or inflammatory"/>
 <result pre="Amgen, human IgG2/kappa), was approved to treat the EGFR-expressing metastatic" exact="colorectal cancer" post="with wild-type KRAS [ 188]. This mAb blocks the"/>
 <result pre="human IgG2/kappa), was approved to treat the EGFR-expressing metastatic colorectal" exact="cancer" post="with wild-type KRAS [ 188]. This mAb blocks the"/>
 <result pre="resulting in the inhibition of EGFR signaling and induction of" exact="cancer" post="cell apoptosis. Two antibody drugs from the XenoMouse are"/>
 <result pre="IgG1), binds to proinflammatory cytokine IL-17α to reduce inflammation in" exact="psoriasis" post="[ 189]. The other is brodalumab (Siliq, Valeant Pharmaceuticals,"/>
 <result pre="two mAb drugs were approved by the US FDA for" exact="psoriasis" post="treatment in 2015 and 2017, respectively. From the HuMabMouse,"/>
 <result pre="B7 on APCs and causing cytotoxic T lymphocytes to kill" exact="cancer" post="cells [ 190]. Nivolumab recognizes to PD-1, reducing inhibitory"/>
 <result pre="[ 191]. Notably, nivolumab was also approved for non-small cell" exact="lung cancer" post="treatment in 2018. Among the mAb drugs derived from"/>
 <result pre="191]. Notably, nivolumab was also approved for non-small cell lung" exact="cancer" post="treatment in 2018. Among the mAb drugs derived from"/>
 <result pre="to ease inflammation. This drug was approved for severe plaque" exact="psoriasis" post="[ 17] in 2009 and for Crohn’s disease ["/>
 <result pre="species. B. anthracis is a fatal pathogen that causes severe" exact="anthrax" post="disease in humans and has been used as a"/>
 <result pre="used as a biological weapon. Although antibiotics are available for" exact="anthrax" post="treatment and as post-exposure prophylaxis, anti-anthrax protective antibodies from"/>
 <result pre="B cell method can enhance phagocytosis to protect against disseminated" exact="candidiasis" post="[ 223]. The single B cell method has also"/>
 <result pre="conducted on the prevention of sexual transmission of HIV-1 and" exact="herpes simplex" post="virus by MB 66 combined with an anti-herpes simplex"/>
 <result pre="simplex virus antibody (AC8) and an anti-HIV antibody (VRC01). Different" exact="influenza" post="viruses cause epidemics ever year, and influenza vaccines are"/>
 <result pre="antibody (VRC01). Different influenza viruses cause epidemics ever year, and" exact="influenza" post="vaccines are the most useful measure to prevent seasonal"/>
 <result pre="235]. MHAA4549A, a human mAb targeting the hemagglutinin stalk of" exact="influenza" post="A virus was cloned from a single human plasmablast"/>
 <result pre="was cloned from a single human plasmablast cell from an" exact="influenza" post="virus vaccinated donor [ 236]. A Phase II clinical"/>
 <result pre="trial of MHAA4549A as a monotherapy for acute uncomplicated seasonal" exact="influenza" post="A in otherwise healthy adults was recently completed (NCT02623322)."/>
 <result pre="(sarilumab and tocilizumab) can be used for the treatment of" exact="rheumatoid arthritis." post="Anti-Factor IXa/Xa antibody (emicizumab) is a valuable treatment for"/>
 <result pre="Willebrand factor antibody (caplacizumab) is approved for the treatment of" exact="thrombotic thrombocytopenic purpura," post="and other antibodies will be approved for new indications"/>
 <result pre="different mechanisms, including mediated pathways (e.g., ADCC/CDC), direct targeting of" exact="cancer" post="cells to induce apoptosis, targeting the tumor microenvironment, or"/>
 <result pre="or targeting immune checkpoints. In mediated pathways, the antibody kills" exact="cancer" post="cells by recruiting natural killer cells or other immune"/>
 <result pre="253] or modification of glycosylation [ 254– 258] to improve" exact="cancer" post="cell killing capabilities. The direct induction apoptosis in cancer"/>
 <result pre="improve cancer cell killing capabilities. The direct induction apoptosis in" exact="cancer" post="cells has traditionally been the preferred mechanism for therapeutic"/>
 <result pre="microenvironment, antibodies can inhibit tumorigenesis by targeting factors involved in" exact="cancer" post="cell growth. For example, Avastin targets vascular endothelial growth"/>
 <result pre="tumor, shutting down the supply of nutrients required for the" exact="cancer" post="cell growth. Immune checkpoints have proven to be valuable"/>
 <result pre="growth. Immune checkpoints have proven to be valuable targets for" exact="cancer" post="treatment. In the future, studies evaluating synergistic effects of"/>
 <result pre="for disease therapy. Antibodies in this category are used for" exact="cancer" post="treatment and elicit cell death by different mechanisms, including"/>
 <result pre="cell death by different mechanisms, including ADCC/CDC, direct targeting of" exact="cancer" post="cells to induce apoptosis, targeting the tumor microenvironment, or"/>
 <result pre="gene for a chimeric T cell receptor-antibody targeting a specific" exact="cancer" post="marker into T cells, such that the engineered cells"/>
 <result pre="T cells, such that the engineered cells target and kill" exact="cancer" post="cells [ 265, 266]. In recent years, this approach"/>
 <result pre="and medical community due to its significant clinical benefits to" exact="cancer" post="patients. In many cases, patients have experienced complete remission"/>
 <result pre="have experienced complete remission or even been completely cured of" exact="cancer" post="[ 267– 271]. Although new methods have been well-established"/>
 <result pre="CDR Complementary-determining region CGRP Calcitonin gene-related peptide CLL Chronic lymphocytic" exact="leukemia" post="CoV Coronavirus CSC Cancer stem cell CTLA-4 Cytotoxic T-lymphocyte–associated"/>
 <result pre="MM Multiple myeloma MSI-H Microsatellite instability high NSCLC Non-small cell" exact="lung cancer" post="PBMC Peripheral blood mononuclear cell PCR Polymerase chain reaction"/>
 <result pre="Multiple myeloma MSI-H Microsatellite instability high NSCLC Non-small cell lung" exact="cancer" post="PBMC Peripheral blood mononuclear cell PCR Polymerase chain reaction"/>
 <result pre="transcription-polymerase chain reaction scFv Single chain fragment variable SLE Systemic" exact="lupus erythematosus" post="TNFα Tumor necrosis factor α US FDA United States"/>
 <result pre="LR Abciximab. An updated review of its use in ischaemic" exact="heart disease" post="Drugs. 1998 56 629 665 10.2165/00003495-199856040-00014 9806109 8. Maloney"/>
 <result pre="anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's" exact="lymphoma" post="Blood. 1997 90 2188 2195 10.1182/blood.V90.6.2188 9310469 9. Maloney"/>
 <result pre="a phase I multiple-dose trial in patients with relapsed non-Hodgkin's" exact="lymphoma" post="J Clin Oncol 1997 15 3266 3274 10.1200/JCO.1997.15.10.3266 9336364"/>
 <result pre="10577977 17. Bartlett BL Tyring SK Ustekinumab for chronic plaque" exact="psoriasis" post="Lancet. 2008 371 1639 1640 10.1016/S0140-6736(08)60702-3 18486724 18. Church"/>
 <result pre="golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with" exact="rheumatoid arthritis" post="J Clin Pharmacol 2007 47 383 396 10.1177/0091270006298188 17322150"/>
 <result pre="a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid" exact="arthritis" post="J Clin Pharmacol 2007 47 383 396 10.1177/0091270006298188 17322150"/>
 <result pre="a novel therapeutic human CD38 monoclonal antibody, induces killing of" exact="multiple myeloma" post="and other hematological tumors J Immunol 2011 186 1840"/>
 <result pre="interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of" exact="influenza" post="and meningococcal vaccinations in healthy subjects: results of an"/>
 <result pre="JG Kricorian G et al. Brodalumab, an anti-interleukin-17-receptor antibody for" exact="psoriasis" post="N Engl J Med 2012 366 1181 1189 10.1056/NEJMoa1109017"/>
 <result pre="S Sher L Skobieranda F et al. Dupilumab in persistent" exact="asthma" post="with elevated eosinophil levels N Engl J Med 2013"/>
 <result pre="a fully human monoclonal antibody against IL-6Ralpha in patients with" exact="rheumatoid arthritis" post="and an inadequate response to methotrexate: efficacy and safety"/>
 <result pre="fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid" exact="arthritis" post="and an inadequate response to methotrexate: efficacy and safety"/>
 <result pre="fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic" exact="colorectal cancer" post="Clin Colorectal Cancer 2006 6 29 31 10.3816/CCC.2006.n.01 16796788"/>
 <result pre="human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal" exact="cancer" post="Clin Colorectal Cancer 2006 6 29 31 10.3816/CCC.2006.n.01 16796788"/>
 <result pre="Blinatumomab for minimal residual disease in adults with B-cell precursor" exact="acute lymphoblastic leukemia" post="Blood. 2018 131 1522 1531 10.1182/blood-2017-08-798322 29358182 43. Oldenburg"/>
 <result pre="for minimal residual disease in adults with B-cell precursor acute" exact="lymphoblastic leukemia" post="Blood. 2018 131 1522 1531 10.1182/blood-2017-08-798322 29358182 43. Oldenburg"/>
 <result pre="minimal residual disease in adults with B-cell precursor acute lymphoblastic" exact="leukemia" post="Blood. 2018 131 1522 1531 10.1182/blood-2017-08-798322 29358182 43. Oldenburg"/>
 <result pre="Grignani G Aglietta M Sangiolo D Next generation immune-checkpoints for" exact="cancer" post="therapy J Thorac Dis 2018 10 S1581 SS601 10.21037/jtd.2018.02.79"/>
 <result pre="safety in 23 458 patients from global clinical trials in" exact="rheumatoid arthritis," post="juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and"/>
 <result pre="23 458 patients from global clinical trials in rheumatoid arthritis," exact="juvenile idiopathic arthritis," post="ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease Ann"/>
 <result pre="from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis," exact="ankylosing spondylitis," post="psoriatic arthritis, psoriasis and Crohn's disease Ann Rheum Dis"/>
 <result pre="clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis," exact="psoriatic arthritis," post="psoriasis and Crohn's disease Ann Rheum Dis 2013 72"/>
 <result pre="in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis," exact="psoriasis" post="and Crohn's disease Ann Rheum Dis 2013 72 517"/>
 <result pre="et al. Adalimumab regulates intracellular TNFalpha production in patients with" exact="rheumatoid arthritis" post="Arthritis Res Ther 2014 16 R153 10.1186/ar4615 25037855 50."/>
 <result pre="al. Adalimumab regulates intracellular TNFalpha production in patients with rheumatoid" exact="arthritis" post="Arthritis Res Ther 2014 16 R153 10.1186/ar4615 25037855 50."/>
 <result pre="25037855 50. Pardoll DM The blockade of immune checkpoints in" exact="cancer" post="immunotherapy Nat Rev Cancer 2012 12 252 264 10.1038/nrc3239"/>
 <result pre="al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's" exact="lymphoma" post="N Engl J Med 2015 372 311 319 10.1056/NEJMoa1411087"/>
 <result pre="M et al. Pembrolizumab for patients with melanoma or non-small-cell" exact="lung cancer" post="and untreated brain metastases: early analysis of a non-randomised,"/>
 <result pre="et al. Pembrolizumab for patients with melanoma or non-small-cell lung" exact="cancer" post="and untreated brain metastases: early analysis of a non-randomised,"/>
 <result pre="60. Paemeleire K MaassenVanDenBrink A Calcitonin-gene-related peptide pathway mAbs and" exact="migraine" post="prevention Curr Opin Neurol 2018 31 274 280 10.1097/WCO.0000000000000548"/>
 <result pre="Warfvinge K Krause DN CGRP as the target of new" exact="migraine" post="therapies - successful translation from bench to clinic Nat"/>
 <result pre="Devalaraja M et al. Raxibacumab for the treatment of inhalational" exact="anthrax" post="N Engl J Med 2009 361 135 144 10.1056/NEJMoa0810603"/>
 <result pre="FDA to review isatuximab as a potential treatment for relapsed/refractory" exact="multiple myeloma." post="Paris, 2019. 67. Richardson PG Attal M Campana F"/>
 <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
 <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
 <result pre="P Hall S et al. Golimumab in patients with active" exact="rheumatoid arthritis" post="despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging"/>
 <result pre="Hall S et al. Golimumab in patients with active rheumatoid" exact="arthritis" post="despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging"/>
 <result pre="VEGFR2 and for inhibiting tumor growth, tumor angiogenesis and/or inducing" exact="cancer" post="cell cytotoxicity. US patent US10,196,447. 2018 February 5. 105."/>
 <result pre="human monoclonal antibody drug and target discovery platform for B-cell" exact="chronic lymphocytic leukemia" post="based on allogeneic hematopoietic stem cell transplantation and phage"/>
 <result pre="antibody drug and target discovery platform for B-cell chronic lymphocytic" exact="leukemia" post="based on allogeneic hematopoietic stem cell transplantation and phage"/>
 <result pre="S Poulsen PC Overgaard LF et al. Selection of a" exact="breast cancer" post="subpopulation-specific antibody using phage display on tissue sections Immunol"/>
 <result pre="Poulsen PC Overgaard LF et al. Selection of a breast" exact="cancer" post="subpopulation-specific antibody using phage display on tissue sections Immunol"/>
 <result pre="JM Peer D Progress and challenges towards targeted delivery of" exact="cancer" post="therapeutics Nat Commun 2018 9 1410 10.1038/s41467-018-03705-y 29650952 122."/>
 <result pre="Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to" exact="prostate cancer" post="cells Mol Cancer Ther 2007 6 2737 2746 10.1158/1535-7163.MCT-07-0140"/>
 <result pre="single chain antibody-mediated intracellular delivery of liposomal drugs to prostate" exact="cancer" post="cells Mol Cancer Ther 2007 6 2737 2746 10.1158/1535-7163.MCT-07-0140"/>
 <result pre="W Yang Y et al. Human neutralizing Fab molecules against" exact="severe acute respiratory syndrome" post="coronavirus generated by phage display Clin Vacc Immunol: CVI"/>
 <result pre="a conserved HA1 epitope has broad neutralizing potency against H5N1" exact="influenza" post="A viruses of different clades Antiviral Research 2013 99"/>
 <result pre="al. Combinatorial antibody libraries from survivors of the Turkish H5N1" exact="avian influenza" post="outbreak reveal virus neutralization strategies Proc Natl Acad Sci"/>
 <result pre="Combinatorial antibody libraries from survivors of the Turkish H5N1 avian" exact="influenza" post="outbreak reveal virus neutralization strategies Proc Natl Acad Sci"/>
 <result pre="Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9" exact="influenza" post="virus. Nat Commun. 2015;6. 133. Wang J, Chen Z,"/>
 <result pre="anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of" exact="rheumatoid arthritis" post="in patients taking concomitant methotrexate: the ARMADA trial Arthritis"/>
 <result pre="necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid" exact="arthritis" post="in patients taking concomitant methotrexate: the ARMADA trial Arthritis"/>
 <result pre="A Paz-Ares L Necitumumab for the treatment of advanced non-small-cell" exact="lung cancer" post="Future Oncol 2019 15 705 716 10.2217/fon-2018-0594 30501503 145."/>
 <result pre="Paz-Ares L Necitumumab for the treatment of advanced non-small-cell lung" exact="cancer" post="Future Oncol 2019 15 705 716 10.2217/fon-2018-0594 30501503 145."/>
 <result pre="A Lopez-Mejia M Ramucirumab in the treatment of non-small cell" exact="lung cancer" post="Expert Opin Drug Saf 2017 16 637 644 10.1080/14740338.2017.1313226"/>
 <result pre="Lopez-Mejia M Ramucirumab in the treatment of non-small cell lung" exact="cancer" post="Expert Opin Drug Saf 2017 16 637 644 10.1080/14740338.2017.1313226"/>
 <result pre="Rodriguez-Vida A Bellmunt J Avelumab for the treatment of urothelial" exact="cancer" post="Expert Rev Anticancer Ther 2018 18 421 429 10.1080/14737140.2018.1448271"/>
 <result pre="Riedl M et al. Icatibant, a new bradykinin-receptor antagonist, in" exact="hereditary angioedema" post="N Engl J Med 2010 363 532 541 10.1056/NEJMoa0906393"/>
 <result pre="M et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary" exact="angioedema" post="N Engl J Med 2010 363 532 541 10.1056/NEJMoa0906393"/>
 <result pre="a fully human anti-epidermal growth factor receptor antibody, in metastatic" exact="colorectal cancer" post="Clin Colorectal Cancer 2005 5 21 23 10.1016/S1533-0028(11)70161-X 15929802"/>
 <result pre="fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal" exact="cancer" post="Clin Colorectal Cancer 2005 5 21 23 10.1016/S1533-0028(11)70161-X 15929802"/>
 <result pre="human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with" exact="rheumatoid arthritis." post="J Rheumatol. 2002;29(11):2288–98. 179. Tyagi Preeta Chu Edward Jain"/>
 <result pre="187. Kreitman, Robert J, et al. Moxetumomab pasudotox in relapsed/refractory" exact="hairy cell leukemia." post="Leukemia. 2018;32(8):1768. 188. Berardi R Onofri A Pistelli M"/>
 <result pre="the evidence for its use in the treatment of metastatic" exact="colorectal cancer" post="Core Evid 2010 5 61 76 10.2147/CE.S7035 21042543 189."/>
 <result pre="evidence for its use in the treatment of metastatic colorectal" exact="cancer" post="Core Evid 2010 5 61 76 10.2147/CE.S7035 21042543 189."/>
 <result pre="NW Clinical and economic review of secukinumab for moderate-to-severe plaque" exact="psoriasis" post="Expert Rev Pharmacoecon Outcomes Res 2016 16 153 166"/>
 <result pre="et al. Rapid cloning of high-affinity human monoclonal antibodies against" exact="influenza" post="virus Nature. 2008 453 667 671 10.1038/nature06890 18449194 216."/>
 <result pre="cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated" exact="candidiasis" post="Nat Commun 2018 9 5288 10.1038/s41467-018-07738-1 30538246 224. Cox"/>
 <result pre="in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic" exact="influenza" post="A antibodies Cell Host Microbe 2013 14 93 103"/>
 <result pre="Estevez A et al. A broadly protective therapeutic antibody against" exact="influenza" post="B virus with two mechanisms of action Nat Commun"/>
 <result pre="10.1158/2326-6066.CIR-14-0029 24795350 242. Sliwkowski MX Mellman I Antibody therapeutics in" exact="cancer" post="Science. 2013 341 1192 1198 10.1126/science.1241145 24031011 243. Makabe"/>
 <result pre="Ghassemi S Milone MC CAR T cell immunotherapy for human" exact="cancer" post="Science. 2018 359 1361 1365 10.1126/science.aar6711 29567707 267. Neelapu"/>
 <result pre="Brudno JN Kochenderfer JN Chimeric antigen receptor T-cell therapies for" exact="lymphoma" post="Nat Rev Clin Oncol 2017 15 31 10.1038/nrclinonc.2017.128 28857075"/>
 <result pre="Tung CP Tsou YL et al. High throughput discovery of" exact="influenza" post="virus neutralizing antibodies from phage-displayed synthetic antibody libraries Sci"/>
</results>
